Depo-Provera
On December 13, 2005, Siskinds filed a class proceeding against Pfizer Canada Inc. and Pfizer Inc. with respect to Depo-Provera. Depo-Provera is typically prescribed to prevent pregnancy, however, it is also used to treat endometriosis and as a palliative treatment of certain cancers. Use of Depo-Provera has been associated with an increased risk of significant bone mineral density loss, including a significantly increased risk of developing osteoporosis at ages below the statistical norm.
• Fresh as Amended Statement of Claim   
• View December 19, 2005 Press Release
On May 28, 2008, the Superior Court of Quebec certified the action as a National Class. Any person who has taken Depo-Provera and has been affected with bone mineral density loss is part of the defined class.
• Notice of Certification [English] [Français]
Siskinds is working cooperatively with the Quebec firm of Belleau Lapointe LLP
For further information concerning this action, please contact Ruth Noble at 1-800-461-6166 ext. 2381 or e-mail Ruth by clicking on the Contact Us link below.
 
Back to Siskinds Actions

The documents available on this page require the latest version of Adobe Acrobat Reader for viewing.
Click Here to download.